Atlanta—New phase 3 clinical trial results point to the potential of several targeted therapies for the treatment of patients with metastatic renal cell carcinoma, a disease with few therapeutic options and an annual worldwide mortality exceeding 100 000.
The studies, presented at the annual meeting of the American Society of Clinical Oncology, held here in June, may change the standard of care for patients with this disease. “The results are likely to lead to an expansion of treatment options for patients with metastatic renal cancer,” said Michael Atkins, MD, of the Beth Israel Deaconess Medical Center's division of Hematology/Oncology, in Boston. “Today, targeted therapy enters the front line for the treatment of renal cancer,” he added.
Hampton T. Trials Probe New Agents for Kidney Cancer. JAMA. 2006;296(2):155-157. doi:10.1001/jama.296.2.155